Fast Facts Newsletter - April (Special Edition) 2025
Summary
Already effective 03/31/2025: Ranibizumab (Cimerli) was withdrawn from the market by the manufacturer on 3/31/25, and current patients on Cimerli may switch to Lucentis or Byooviz without a new prior authorization. Already effective 06/01/2025: Cohere Health's coverage criteria policies applicable to Commercial plans and Medicaid plans were revised for a list of cardiovascular and musculoskeletal procedures, including cardiac ablation, spinal cord stimulators, knee arthroplasty and kyphoplasty.
Get alerts when payers change rules like this one
We check HealthPartners and other payers every day and email you when a change matches your specialty and state.